The grants review process

Alzheimer’s Research UK is a member of the Association of Medical Research Charities and follows their guidelines for best practice in peer review. Grants are awarded on scientific merit in relation to Alzheimer's Research UK’s remit and on the basis of open competition.

The quality of the application and applicants are the key determinants of outcome, although the strength of the dementia research environment within the institution is also considered.                    

Grants are reviewed within distinct advisory groups, depending on the grant scheme applied to and the expertise required to review them. It is therefore important that applications are submitted to the most appropriate grant scheme. Please refer to the grant schemes page for more information on the review process.

The advisory groups are provided with comments from a range of external dementia experts who kindly volunteer their time to conduct detailed and valuable reviews of grant applications in their area of expertise. A list of the peer reviewers that have helped us in the last three years can be found here. Our conflict of interest policy can be found here.

Applications for research studies that involve people require lay review. Applicants are requested to complete a lay summary of their application which is sent to lay review volunteers for comments. The comments made by lay reviewers are made available to the reviewing board members.

Our review panels

Grant Review Board

This distinguished group of some of the world’s leading dementia research experts reviews the applications we receive to most of our grant schemes before making recommendations to our Trustees.

  • Chair – Dr Tara Spires-Jones, University of Edinburgh – Chancellor’s Fellow and Reader, School of Biomedical Sciences
  • Professor Johannes Attems, Newcastle University – Director, Newcastle Brain Tissue Resource, Institute for Ageing and Health
  • Dr Delphine Boche, University of Southampton – Associate Professor in Clinical Neuroimmunopathology, Department of Medicine
  • Professor David Brooks, Imperial College London – Hartnett Professor of Neurology, Department of Medicine
  • Dr Michael Coleman, The Babraham Institute – Professor, Department of Clinical Neurosciences
  • Dr Alexander Gerhard, University of Manchester – Senior Lecturer in Neurology, Wolfson Molecular Imaging Centre, Deputy Centre Lead for Clinical and Cognitive Neurosciences at the Institute for Brain, Behaviour and Mental Health
  • Professor Lesley Jones, Cardiff University – Professor of Neurogenetics, School of Medicine
  • Dr Rick Livesey, University of Cambridge – Wellcome Trust Group Leader, Biochemistry Department/Gurdon Institute
  • Dr David Llewellyn, University of Exeter – Senior Research Fellow in Clinical Epidemiology, Medical School
  • Dr Katie Lunnon, University of Exeter – Senior Lecturer in Epigenetics, Medical School
  • Dr Jody Mason, University of Bath – Senior Lecturer, Department of Biology and Biochemistry
  • Professor Simon Mead, University College London – Honorary Professor, Institute of Neurology
  • Dr Wendy Noble, King’s College London – Senior Lecturer in Neuroscience, Institute of Psychiatry, Psychology and Neuroscience
  • Dr Michael O’Neill, Lilly – Head of Molecular Pathology Group
  • Professor Bettina Platt, University of Aberdeen – Chair in Translational Neuroscience, School of Medical Sciences
  • Dr Jill Richardson, GSK and Imperial College London – Director, External Alliances and Development
  • Professor Patricia Salinas, University College London – Professor of Cellular Neurobioloy, Division of Biosciences
  • Dr John-Paul Taylor, Newcastle University – Clinical Senior Lecturer, Institute of Neuroscience, Honorary Consultant in Old Age Psychiatry
  • Professor Stephen Wharton, University of Sheffield – Professor and Honorary consultant in Neuropatholgy, Department of Neuroscience
  • Dr Robert Williams, University of Bath – Reader, Department of Biology and Biochemistry
Clinical Trials Advisory Panel

The Clinical Trials Advisory Panel (CTAP) is composed of UK and international experts on dementia, statistics, clinical pharmacology and research governance. Members of the CTAP generously give their time to review the Global Clinical Trials Fund applications we receive before making recommendations to our Trustees.

  • Professor Nick Fox, University College London – Professor of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Institute of Neurology
  • Professor Chris Frost, London School of Hygiene and Tropical Medicine – Professor of Medical Statistics, Department of Medical Statistics
  • Dr Les Huson, Imperial College – Honorary Lecturer in Medical Statistics, Centre for Pharmacology and Therapeutics, Division of Experimental Medicine
  • Dr Vincenzo Libri, University College London – Head of The Leonard Wolfson Experimental Neurology Centre, Institute of Neurology & The National Hospital for Neurology and Neurosurgery
  • Professor Colin Masters, University of Melbourne – Executive Director, Mental Health Research Institute and Laureate Professor
  • Professor John O’Brien, University of Cambridge – Foundation Professor of Old Age Psychiatry, Department of Psychiatry
  • Professor Craig Ritchie, University of Edinburgh – Professor of the Psychiatry of Ageing, Centre for Clinical Brain Sciences, University of Edinburgh
  • Professor Peter Passmore, Queen’s University Belfast – School of Medicine, Dentistry and Biomedical Sciences, Centre for Public Health
  • Dr Peter Watson, University of Cambridge – Statistician at the MRC Cognition and Brain Sciences Unit
  • Professor David Rubinsztein, University of Cambridge – Professor of Molecular Neurogenetics, Academic Lead of the Alzheimer’s Research UK Cambridge Drug Discovery Institute and Deputy Director of the Cambridge Institute of Medical Research
  • Professor Karl Herholz, University of Manchester – Professor of Clinical Neuroscience
  • Dr Shahid Zaman, University of Cambridge – consultant psychiatrist and a neuroscientist
  • Dr Iracema Leroi, University of Manchester, Clinical Senior Lecturer, Institute of Brain Behaviour and Mental Health
    Honorary Consultant Psychiatrist, Manchester Mental Health and Social Care Trust
  • Professor Jane Armitage, University of Oxford, Professor of Clinical Trials and Epidemiology
  • Professor Nicola Lautenschlager, University of Melbourne, Professor of Psychiatry of Old Age
Dementia Consortium

The Dementia Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration. The progression of each application is assessed by the Dementia Consortium partners and by a panel of drug discovery experts associated with the MRCT Centre for Therapeutics Discovery.

  • MRCT representation: Justin Bryans, Director; Katy Kettleborough, Associate Director, Biology; David Matthews, Associate Director, BioTherapeutics; Andy Merritt, Associate Director, Chemistry
  • Lilly representation: Dr Mike Hutton, Chief Scientific Officer for neurodegeneratice diseases and Hugh Nuttall, Research Advisor
  • Eisai representation: Andrew Takle, Director, Open Innovation and Peter Atkinson, Associate Director
  • Astex representation: Lee Dawson, VP Head of CNS
  • Abbvie representation: Eric Karran, Vice President
  • MSD representation: Joel Schachter, Collaboration Lead for Neuroscience
  • ARUK representation: Dr David Reynolds, Chief Scientific Officer, Dr Rosa Sancho, Head of Research and Dr Tara Spires Jones, University of Edinburgh